1. Home
  2. UTHR vs PPC Comparison

UTHR vs PPC Comparison

Compare UTHR & PPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UTHR
  • PPC
  • Stock Information
  • Founded
  • UTHR 1996
  • PPC 1946
  • Country
  • UTHR United States
  • PPC United States
  • Employees
  • UTHR N/A
  • PPC N/A
  • Industry
  • UTHR Biotechnology: Pharmaceutical Preparations
  • PPC Meat/Poultry/Fish
  • Sector
  • UTHR Health Care
  • PPC Consumer Staples
  • Exchange
  • UTHR Nasdaq
  • PPC Nasdaq
  • Market Cap
  • UTHR 14.4B
  • PPC 12.5B
  • IPO Year
  • UTHR 1999
  • PPC 1987
  • Fundamental
  • Price
  • UTHR $297.02
  • PPC $45.03
  • Analyst Decision
  • UTHR Buy
  • PPC Hold
  • Analyst Count
  • UTHR 13
  • PPC 6
  • Target Price
  • UTHR $383.08
  • PPC $48.67
  • AVG Volume (30 Days)
  • UTHR 561.1K
  • PPC 1.2M
  • Earning Date
  • UTHR 07-30-2025
  • PPC 07-30-2025
  • Dividend Yield
  • UTHR N/A
  • PPC 13.98%
  • EPS Growth
  • UTHR 18.86
  • PPC 145.39
  • EPS
  • UTHR 25.10
  • PPC 5.08
  • Revenue
  • UTHR $2,994,100,000.00
  • PPC $17,979,366,000.00
  • Revenue This Year
  • UTHR $14.58
  • PPC $2.74
  • Revenue Next Year
  • UTHR $6.34
  • PPC $1.19
  • P/E Ratio
  • UTHR $11.77
  • PPC $8.87
  • Revenue Growth
  • UTHR 19.84
  • PPC 2.40
  • 52 Week Low
  • UTHR $266.98
  • PPC $37.28
  • 52 Week High
  • UTHR $417.82
  • PPC $57.16
  • Technical
  • Relative Strength Index (RSI)
  • UTHR 51.32
  • PPC 40.29
  • Support Level
  • UTHR $286.68
  • PPC $44.80
  • Resistance Level
  • UTHR $301.75
  • PPC $46.13
  • Average True Range (ATR)
  • UTHR 6.73
  • PPC 1.04
  • MACD
  • UTHR 1.81
  • PPC 0.09
  • Stochastic Oscillator
  • UTHR 77.16
  • PPC 26.46

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

About PPC Pilgrim's Pride Corporation

Pilgrim's Pride is the second-largest poultry producer in the US (59% of 2024 sales), the UK (29% including other European sales), and Mexico (12%). Its UK and European arm also includes pork operations from the 2019 acquisition of Tulip. Pilgrim's sells to chain restaurants, food processors, food distributors, and retail chains. most of its US and Mexican sales come from fresh chicken, while prepared chicken and pork constitute most of its UK and European sales. JBS owns more than 80% of Pilgrim's Pride's outstanding shares, though it failed to acquire the remaining stake in 2021 after a special board committee deemed JBS' offer undervalued Pilgrim's Pride.

Share on Social Networks: